Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bendamustine + dasatinib
- Development stage
- Unknown
- Lead developer
- Bristol Myers Squibb
- Modality
- Small Molecules
- Administration
- Intravenous, Oral
01
Overview
**Bendamustine + dasatinib** is a combination of two small molecule anticancer drugs, each with distinct mechanisms of action. Bendamustine is an alkylating agent (a nitrogen mustard derivative) that forms DNA crosslinks, leading to cell death in both dividing and non-dividing cells. It is primarily used for the treatment of chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin lymphoma (NHL)[1][8]. Dasatinib is a second-generation tyrosine kinase inhibitor that targets multiple kinases including BCR-ABL, SRC family kinases, c-KIT, EPHA2, and PDGFRβ. It inhibits the proliferation of cancer cells by blocking abnormal signaling pathways involved in Philadelphia chromosome-positive chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL)[3][4][5][6]. The combination may be explored for synergistic effects in hematologic malignancies.
- Other names
- none
02
Targets
EPHA2 (Ephrin type-A receptor 2)ABL1 (ABL proto-oncogene 1, non-receptor tyrosine kinase)DNAKIT (c-KIT proto-oncogene receptor tyrosine kinase)SFK (SRC family kinases)PDGFRB (Platelet-derived growth factor receptor beta)
Beyond the preview
Go deeper on bendamustine + dasatinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bendamustine + dasatinib.